Coutinho Ana J, Costa Lima Sofia A, Afonso Carlos M M, Reis Salette
LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemistry, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), Edifício do Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4050-208 Matosinhos, Porto, Portugal.
Int J Biol Macromol. 2020 Apr 30;158:180-188. doi: 10.1016/j.ijbiomac.2020.04.233.
Considering the potential of mucoadhesive properties of nanoparticles in oral delivery, this work describes the preparation and characterization of fucoidan/chitosan nanoparticles loaded with methotrexate (MTX) intended to lung cancer therapy. The nanoparticles were produced and characterized in terms of size, surface charge, entrapment efficiency, and morphology. The size of the developed nanoparticles was around 300 nm, the zeta potential value was negative (ca. -30 mV), revealing a low tendency to aggregate. The self-assembled fucoidan/chitosan nanoparticles were stable at acidic pH (1.6-5.2), without disintegration under pH 6-7.4, revealing resistance through the gastrointestinal tract, and were found to be mucoadhesive suggesting ability to enhance drug oral bioavailability. Lung cancer cells quickly internalized the developed nanoparticles. Moreover, MTX-loaded fucoidan/chitosan nanoparticles up to 245 μg mL in polymer equivalent to 23.5 μg mL of MTX were safe towards fibroblasts but hampered lung cancer cell proliferation mediated by an apoptotic process. MTX-loaded nanoparticles were 7-fold more effective in inhibiting lung cancer cells proliferation than the free drug, showing the potential of fucoidan-chitosan nanoparticles to improve the cytotoxicity of free methotrexate on A549 lung cancer cells. These results also demonstrate that fucoidan/chitosan nanoparticles may provide a suitable platform for poor-water soluble compounds' oral delivery.
考虑到纳米颗粒在口服给药中的黏膜黏附特性潜力,本研究描述了负载甲氨蝶呤(MTX)用于肺癌治疗的岩藻依聚糖/壳聚糖纳米颗粒的制备与表征。对纳米颗粒的尺寸、表面电荷、包封率和形态进行了测定和表征。所制备纳米颗粒的尺寸约为300 nm,zeta电位值为负(约 -30 mV),表明其聚集倾向较低。自组装的岩藻依聚糖/壳聚糖纳米颗粒在酸性pH值(1.6 - 5.2)下稳定,在pH值6 - 7.4时不会崩解,显示出其在胃肠道中的耐受性,且具有黏膜黏附性,表明其具有提高药物口服生物利用度的能力。肺癌细胞能迅速摄取所制备的纳米颗粒。此外,聚合物中负载MTX的岩藻依聚糖/壳聚糖纳米颗粒浓度高达245 μg/mL(相当于23.5 μg/mL的MTX)对成纤维细胞是安全的,但通过凋亡过程阻碍肺癌细胞增殖。负载MTX的纳米颗粒在抑制肺癌细胞增殖方面比游离药物有效7倍,显示出岩藻依聚糖 - 壳聚糖纳米颗粒提高游离甲氨蝶呤对A549肺癌细胞细胞毒性的潜力。这些结果还表明,岩藻依聚糖/壳聚糖纳米颗粒可能为难溶性化合物的口服给药提供一个合适的平台。